ライフサイエンスコーパス: IGF-binding protein

1 s a growth-suppressing factor, as well as an IGF-binding protein.

2 by transmembrane receptors and modulated by IGF-binding proteins.

3 GF signalling by the increased expression of IGF-binding proteins.

4 een insulin-like growth factor 1 (IGF-I) and IGF binding protein 1 (IGFBP-1) have recently been disco

5 calcium, zinc, and sodium] and serum IGF-I, IGF binding protein 1 (IGFBP-1), IGF binding protein 3 (

6 selected from IGF-1 (n = 9), IGF-2 (n = 1), IGF binding protein 1 (IGFBP1; n = 3), IGFBP3 (n = 3), a

7 trypsin, alpha-fetal protein, ceruloplasmin, IGF binding protein 1, transferrin, apolipoprotein(AI) [

8 uble human IGF-I receptor, recombinant human IGF-binding protein 1, and sIGF-II/MPR with similar kine

9 sulin dose, or circulating concentrations of IGF-binding proteins 1 and 3.

10 or the immunoreactivities (ir) of the IGF-I, IGF binding protein-1 (IGFBP-1) and glycogen synthase ki

11 The insulin/IGF binding protein-1 (IGFBP-1) axis is important in coo

12 hat insulin-like growth factor-I (IGF-I) and IGF binding protein-1 (IGFBP-1) could be important deter

13 a), insulinlike growth factor-I (IGF-I), and IGF binding protein-1 (IGFBP-1) in 14 subjects with CF (

14 IGF binding protein-1 (IGFBP-1) is a downstream target o

15 IGF binding protein-1 (IGFBP-1) is a secretory product o

16 y that IGF-I is dependent on the presence of IGF binding protein-1 (IGFBP-1) to act as a wound healin

17 IGF binding protein-1 (IGFBP-1), a hepatocyte-derived se

18 Fasting IGF binding protein-1 concentration was associated with

19 ene under the transcriptional control of the IGF binding protein-1 insulin response element.

20 ns with time were statistically significant (IGF binding protein-1, P-heterogeneity = .0016; sIL6R, P

21 otein-3 levels, and an increase in levels of IGF binding protein-1.

22 free testosterone with increases in SHBG and IGF binding protein-1.

23 oncentrations of insulin-like growth factor (IGF) binding protein-1 (IGFBP1) are associated with insu

24 had higher serum insulin-like growth factor (IGF) binding protein-1 levels (21.0 +/- 8.9 ng/mL versus

25 G6Pase, and a third insulin-regulated gene, IGF-binding protein-1 (IGFBP1); suggests a high degree o

26 The role of IGF binding protein 2 (IGFBP2) in cell growth is intrigu

27 HMGA1 suppresses the abundance of IGF binding protein 2/IGFBP2 and Grb14, inhibitors of IG

28 we identified angiopoietin-like proteins and IGF-binding protein 2 (IGFBP2) as new hormones that, tog

29 Addition of either angiopoietin-like 5 or IGF-binding protein 2 to the cultures led to a sizable e

30 Elevated serum levels of IGF-binding protein 2 were observed to correlate with ad

31 IGF binding protein-3 levels, and increased IGF binding protein-2 levels, a pattern suggestive of di

32 was accompanied by a significant increase in IGF binding protein-2 levels, a slight reduction in IGF

33 sion was associated with increased levels of IGF-binding protein-2 (IGFBP-2) in the uterus and ovary,

34 , IGF-I is ultrafiltered in conjunction with IGF-binding protein-2 and is present in proximal tubular

35 Plasma IGF-I and IGF binding protein 3 (IGFBP-3) concentrations and molar

36 Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood s

37 150-kDa complex including the IGF molecule, IGF binding protein 3 (IGFBP-3), and the acid labile sub

38 erum IGF-I, IGF binding protein 1 (IGFBP-1), IGF binding protein 3 (IGFBP-3), and the IGF-I:IGFBP-3 m

39 F-I) concentrations, frequently adjusted for IGF binding protein 3 (IGFBP-3), have been associated wi

40 Notably, injection of IGF-1 plus IGF binding protein 3 (IGFBP3), but not injection of IGF

41 n assessment using Western blot analysis for IGF binding protein 3 (IGFBP3), IGF-1 receptor (IGF-1R),

42 iously diminished muscle levels of IGF-1 and IGF binding protein 3 both increased following PRT (P <

43 F-I) and the concentration ratio of IGF-I to IGF binding protein 3 were lower in the low-protein, low

44 ternary complex formed by the association of IGF binding protein 3-IGF complexes with a serum protein

45 analyzed for leptin, adiponectin, IGF1, and IGF binding protein 3.

46 ed, as were hematocrit (Hct), Ep, IGF-1, and IGF-binding protein 3 (IGF-BP3) levels.

47 ix et al. demonstrate that downregulation of IGF-binding protein 3 (IGFBP-3) and -4, the negative reg

48 led that GR cells exhibited markedly reduced IGF-binding protein 3 (IGFBP-3) and IGFBP-4 RNA.

49 pproximately 13-fold (P < 0.001) increase in IGF-binding protein 3 (IGFBP-3) protein levels were also

50 like growth factor (IGF-I) content and IGF-I:IGF-binding protein 3 (IGFBP-3) ratio as risk factors fo

51 complexes with acid-labile subunit (ALS) and IGF-binding protein 3 (IGFBP-3) to maintain its circulat

52 owth factor I (IGF-I) and/or lower levels of IGF-binding protein 3 (IGFBP-3).

53 een insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP3) so that the free form of

54 1 signaling by ablating IGF-1 and increasing IGF-binding protein 3, increased vSMC apoptosis, and dec

55 to direct expression of rat IGF-I and human IGF binding protein-3 (IGFBP-3) to mammary tissue during

56 thors assessed the associations of IGF-1 and IGF binding protein-3 (IGFBP-3) with cardiovascular dise

57 However, des(1-3)IGF-I, which weakly binds IGF binding protein-3 (IGFBP-3), induced IGF-IR phosphor

58 proteins insulin-like growth factor (IGF) 1, IGF binding protein-3 and acid-labile subunit, along wit

59 Concomitant administration of IGF binding protein-3 blocked IGF-1-positive inotropic a

60 Suppression of IGF binding protein-3 by palmitate promotes hepatic infl

61 ding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels

62 1% decrease at 1 and 2 wk, respectively) and IGF binding protein-3 levels, and increased IGF binding

63 r risk factors, including circulating IGF-I, IGF binding protein-3, and C-peptide.

64 r insulin, glucose, total IGF-I, free IGF-I, IGF binding protein-3, and estradiol.

65 evels of insulin-like growth factor (IGF)-1, IGF binding protein-3, growth hormone (GH), and somatost

66 rmone, insulin-like growth factor-I (IGF-1), IGF binding protein-3, insulin, cortisol, parathyroid ho

67 cose, insulin, insulin-like growth factor-I, IGF binding protein-3, leptin, or body weight gain.

68 ALS retains the IGF binding protein-3-IGF complexes in the vascular comp

69 IGF-II (Ptrend=0.006 for both) but not with IGF binding protein-3.

70 Similar associations were observed for IGF binding protein-3.

71 n, insulin-like growth factor-I (IGF-I), and IGF binding protein-3.

72 Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is known to block IGF a

73 Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) promotes apoptosis of c

74 Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) can stimulate apoptosis

75 ed and validated insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) as a novel miR-21 target

76 This article presents IGF-binding protein-3 (IGFBP-3) as a new modulator of ap

77 IGF-binding protein-3 (IGFBP-3) influences IGF action di

78 IGF-binding protein-3 (IGFBP-3) is a liver-derived, anti

79 IGF-binding protein-3 (IGFBP-3) is the major carrier for

80 Serum IGF-binding protein-3 (IGFBP-3) was significantly lower

81 Subsequently, IGF-1- and IGF-binding protein-3 (IGFBP-3) were analyzed using enzy

82 IGF-binding protein-3 (IGFBP3) is a member of the IGFBP

83 nation of the specificity and sensitivity of IGF-binding protein-3 as an index of nutrition or anabol

84 on into the study and was analyzed for serum IGF-binding protein-3 concentration (by radioimmunoassay

85 IGF-binding protein-3 concentration at the time of admis

86 Variability in IGF-binding protein-3 concentration could not be explain

87 y should be considered when evaluating serum IGF-binding protein-3 concentrations as a marker of nutr

88 F-1 concentrations changed coordinately with IGF-binding protein-3 concentrations in females and male

89 s of the present study were to measure serum IGF-binding protein-3 concentrations in trauma patients

90 y must be considered when interpreting serum IGF-binding protein-3 concentrations in trauma patients.

91 In women, serum IGF-binding protein-3 concentrations were increased with

92 der were not significant predictors of serum IGF-binding protein-3 concentrations when all patients w

93 on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 gene expression.

94 cal illness, but there is little research on IGF-binding protein-3, which regulates the bioactivity o

95 eness in vitro through regulated cleavage of IGF-binding protein 4 (IGFBP4).

96 It was found that IGF binding protein 5 (IGFBP-5), as well as three IGFs e

97 had no effect on apolipoprotein D (ApoD) or IGF binding protein 5 (IGFBP5) expression, but E2/T and

98 n, muscle creatine kinase, beta-enolase, and IGF binding protein 5 and activated the myocyte enhancer

99 H (but not other myofibrillar proteins) and IGF binding protein 5, which may favor cell protein loss

100 parin binding to insulin-like growth factor (IGF)-binding protein 5 (IGFBP-5) leads to a 17-fold decr

101 Overexpression of IGF-binding protein 5 (IGFBP-5) in the human hair xenogr

102 ociated with fibrosis, including Wnt and IGF/IGF-binding protein 5 (IGFBP5).

103 ously shown that insulin-like growth factor (IGF) binding protein- 5 (IGFBP-5) is overexpressed in lu

104 IGF binding protein-5 (BP-5) is an important bone format

105 Therefore, elucidation of the identity of IGF binding protein-5 (BP-5) protease produced by osteob

106 We investigate whether local IGF binding protein-5 (IGFBP-5) promotes the myogenic ac

107 vel of upstream signaling molecules, such as IGF binding protein-5 (IGFBP-5), IGF-1 receptor (IGF-1R)

108 determine whether IGF-I action was altered, IGF binding protein-5, which is synthesized in response

109 Recent studies support the concept that IGF-binding protein-5 (IGFBP-5) stimulates bone formatio

110 sed in MK-PTEN mammary tissue, including the IGF-binding protein-5 (Igfbp5) gene, and others whose ex

111 oped a myogenic cell line that overexpresses IGF-binding protein-5.

112 role of TEC-expressed insulin growth factor (IGF) binding protein-7 (IGFBP7/angiomodulin).

113 e inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for r

114 ical properties such as the interaction with IGF binding proteins and self-aggregation.

115 his IGF-II 'binding-hotspot', revealing that IGF-binding proteins and IGF2R have converged on the sam

116 BI-31772, which displaces IGF-I from all six IGF-binding proteins at low nanomolar concentrations fro

117 etween common genetic variation in the IGF1, IGF binding protein (BP) 1, and IGFBP3 genes with IGF-I

118 plasma levels of insulin-like growth factor (IGF) binding protein (BP)-2 or IGFBP-3 would predict can

119 on of insulin-like growth factor (IGF)-I and IGF-binding protein (BP) 3 with cancer and cardiovascula

120 fically cleaving insulin-like growth factor (IGF) binding proteins, causing increased IGF bioavailabi

121 and tissues is controlled by members of the IGF binding protein family (IGFBP).

122 s (A6-A11, A7-B7, and A20-B19) maintained by IGF-binding proteins; IGF-swap has alternative pairing (

123 uded demonstrating the effectiveness of IGF1/IGF binding protein (IGF1/IGFBP) complex dissociation us

124 levels of IGF-I with concomitant lowering of IGF binding protein (IGFBP)-3 are associated with increa

125 Serum concentrations of IGF-I, IGF binding protein (IGFBP)-3, and their molar ratio (IG

126 Levels of IGF-1, IGF-2, IGF binding proteins (IGFBP) 1-3, and IL-6 were measured

127 isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid delet

128 ) IGF-1, which has a much lower affinity for IGF binding proteins (IGFBP) than IGF-1.

129 Since IGF-1 action is influenced by IGF binding proteins (IGFBP), this study was conducted t

130 he expression of insulin-like growth factor (IGF)-binding protein (IGFBP)-1, a secreted protein that

131 Insulin-like growth factor (IGF)-binding protein (IGFBP)-6 decreases cancer cell pro

132 kDa consisting of one molecule each of IGF, IGF-binding protein (IGFBP) 3, and an acid labile subuni

133 Investigating IGF-binding protein (IGFBP) modulation of IGF-II actions

134 ired for expression of genes encoding IGF-2, IGF-binding protein (IGFBP)-2 and IGFBP-3.

135 ) complexed with its natural binding protein IGF-binding protein (IGFBP)-3 (rhIGF-I/IGFBP-3) is a nov

136 muscle, while recent evidence suggests that IGF-binding protein (IGFBP)-3 acts as an insulin antagon

137 th and increases lymphocyte numbers and that IGF-binding protein (IGFBP)-3 has an opposing effect, in

138 In this study, the endogenous expression of IGF-binding protein (IGFBP)-3 was examined in human reti

139 tor I (IGF-I) knockout mice demonstrate that IGF-binding protein (IGFBP)-5, an important bone formati

140 e is still little information about IGFs and IGF-binding proteins (IGFBP) in cancers detected by the

141 questered into binary complexes with several IGF-binding proteins (IGFBP-2, IGFBP-3, and IGFBP-5).

142 reatment of cells with either alphaIR3 or an IGF-binding protein, IGFBP-3, led to a 75% inhibition of

143 atients further revealed elevated IGF-II and IGF binding proteins IGFBP4 and IGFBP6.

144 ong induction of insulin-like growth factor (IGF)-binding protein IGFBP5, an antagonist of IGF signal

145 rowth, the specific contributions of the six IGF binding proteins (IGFBPs 1-6) to these processes are

146 els of insulin-like growth factor 1 (IGF-1), IGF binding proteins (IGFBPs) 1 and 3, insulin, osteocal

147 IGF binding proteins (IGFBPs) modify IGF-I actions indep

148 Because IGF binding proteins (IGFBPs) play a critical role in mo

149 The IGF binding proteins (IGFBPs) represent a class of natur

150 IGFs are bound to IGF binding proteins (IGFBPs), which modulate IGF ligand

151 eptors and modulated by a family of secreted IGF binding proteins (IGFBPs).

152 activity is regulated tightly by a family of IGF binding proteins (IGFBPs).

153 studies to be important for association with IGF binding proteins (IGFBPs).

154 The insulin-like growth factor (IGF) binding proteins (IGFBPs) modulate the actions of t

155 However, an unrelated class of proteins, the IGF-binding proteins (IGFBPs) also bind IGF-1 in the ser

156 on bone, and alterations in the IGFs and/or IGF-binding proteins (IGFBPs) could be responsible for t

157 Given that several secreted IGF-binding proteins (IGFBPs) exist in mammals, our work

158 le of insulin-like growth factor (IGF)-I and IGF-binding proteins (IGFBPs) in the regulation of vascu

159 between IGF-1/2, the IGF-1 receptor, and the IGF-binding proteins (IGFBPs) leads to elevated IGF-1 se

160 Specific IGF-binding proteins (IGFBPs) modulate the interaction o

161 of insulin-like growth factor I (IGF-I) and IGF-binding proteins (IGFBPs) occur in children with end

162 metabolism yet control of their activity by IGF-binding proteins (IGFBPs) remains controversial.

163 The ability of IGF-binding proteins (IGFBPs) such as IGFBP-3 to reduce

164 mainly by the liver and circulates bound to IGF-binding proteins (IGFBPs), either as binary complexe

165 Thus, inhibitors of IGF-binding proteins (IGFBPs), especially IGFBP-3, could

166 F) signaling through proteolytic cleavage of IGF-binding proteins (IGFBPs).

167 , distinctive for the pivotal roles of local IGF-binding proteins (IGFBPs).

168 of high affinity, specific binding proteins (IGF-binding proteins; IGFBPs) that are present in the in

169 get genes 4E-BP and l (2)efl and the insulin/IGF-binding protein IMP-L2.

170 An excess of one or more of the six IGF binding proteins in the 35-kD serum fractions result

171 59, 60, Ala31)hIGF-I] with high affinity to IGF-binding proteins (Ki = 0.3-3.9 nM) and no biological

172 Neither IGF-1 analogues with low affinity to IGF binding proteins nor proteinase inhibitors obliterat

173 nding protein 4 (IGFBP-4), the most abundant IGF-binding protein produced by rodent smooth muscle cel

174 IGF-I, rescued from structural ambiguity by IGF-binding proteins, reflects fine-tuning of signal tra

175 re medium (R0), and to avoid interference by IGF-binding proteins, secreted IGF peptides were isolate

176 ound mostly to a family of six high affinity IGF-binding proteins, which form stable complexes with I